Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571900 | 0.78 | HSD11B1 (0.41) | TSHRGAACYP1A2ICMTOPRM1 | |
| SCHEMBL27360942 | 0.69 | ICMT (0.37) | TSHRGAAICMT | |
| SCHEMBL28251031 | 0.68 | DPP4 (0.42) | PNMT | |
| SCHEMBL28249607 | 0.67 | TSHR (0.43) | TSHRGAACYP1A2ICMTOPRM1 | |
| SCHEMBL15630944 | 0.66 | CHRNB2 (0.39) | PNMT | |
| SCHEMBL2360103 | 0.65 | OPRM1 (0.41) | TSHRPNMTCYP1A2ICMTOPRM1 | |
| SCHEMBL10090781 | 0.65 | — | — | |
| SCHEMBL28216267 | 0.64 | HTR1A (0.39) | PNMT | |
| SCHEMBL15684552 | 0.63 | OPRM1 (0.39) | TSHRPNMTCYP1A2ICMTOPRM1 | |
| SCHEMBL1664714 | 0.63 | TSHR (0.47) | TSHRGAACYP1A2ICMTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741044-B2 | Libraries of oligomers labeled with different tags | OXFORD GENE TECHNOLOGY IP LIMITED | 2010-06-22 | — | — | US | disclosed |
| US-20090029866-A1 | Libraries of oligomers labeled with different tags | OXFORD GENE TECHNOLOGY IP LIMITED | 2009-01-29 | — | — | US | disclosed |
| US-7399846-B2 | Libraries of oligomers labeled with different tags | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2008-07-15 | — | — | US | disclosed |
| US-20050003408-A1 | Libraries of oligomers labeled with different tags | ISIS INNOVATION LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| US-6780981-B1 | MAKING A SET OF LABELLED COMPOUNDS BY THE USE OF PARTICULATE SUPPORT, COMPRISES DIVIDING THE SUPPORT INTO LOTS, PERFORMING A DIFFERENT CHEMICAL REACTION ON EACH LOT OF THE SUPPORT | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| EP-1428810-A2 | Libraries of oligomers labelled with different tags | Oxford Gene Technology IP Limited (GB) | 2004-06-16 | — | — | EP | disclosed |
| EP-1068216-B1 | LIBRARIES OF OLIGOMERS LABELLED WITH DIFFERENT TAGS | ISIS INNOVATION (GB) | 2003-12-10 | — | — | EP | disclosed |
| EP-1068216-A2 | LIBRARIES OF OLIGOMERS LABELLED WITH DIFFERENT TAGS | ISIS INNOVATION LIMITED (GB) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999060007-A2 | LIBRARIES OF OLIGOMERS LABELLED WITH DIFFERENT TAGS | ISIS INNOVATION LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |
| EP-0246196-A1 | Optically active iridium complexes, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029866-A1 | Libraries of oligomers labeled with different tags | FBL, HNRNPL, MTREX | TSHR 3462/4885PNMT 747/4885GAA 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.